West Nile Virus

West Nile Virus — scientific infographic poster

Table of Contents

  1. Overview
  2. Pathogen and Biology
  3. Transmission and Vector Biology
  4. Incubation and Disease Spectrum
  5. Symptoms and Clinical Presentation
  6. Diagnosis
  7. Treatment
  8. Home Care and Supportive Management
  9. Complications
  10. Prevention
  11. Key Research Papers
  12. Connections
  13. Featured Videos

1. Overview

West Nile Virus (WNV) is a mosquito-borne flavivirus that has become the leading cause of domestically acquired arboviral encephalitis in the United States since it was introduced to North America in 1999. The virus was first isolated from a febrile woman in the West Nile district of Uganda in 1937, remained primarily an Old World pathogen for decades, and then emerged dramatically in New York City in the summer of 1999, rapidly spreading across the entire continental US by 2004.

The epidemiologic spectrum of WNV infection is heavily skewed: approximately 80% of infected people have no symptoms at all. About 20% develop a self-limited febrile illness called West Nile fever. Fewer than 1% develop West Nile neuroinvasive disease (WNND) — meningitis, encephalitis, or acute flaccid paralysis — which carries significant mortality and long-term morbidity.

From 1999 through 2022, the U.S. Centers for Disease Control and Prevention (CDC) reported over 56,000 cases of WNV disease in the United States, including more than 27,000 neuroinvasive cases and over 2,800 deaths. Because only symptomatic (and particularly severe) cases are typically reported, total infections are estimated in the millions over this period. There is no licensed vaccine or specific antiviral treatment for WNV in humans. Prevention depends entirely on mosquito control and personal protection.

In 2024, U.S. states reported 1,808 West Nile disease cases, below the 10-year median of 2,162. In 2023 they reported 2,628. Among all mosquito- and tick-borne virus disease cases reported in 2023 (2,770, of which West Nile made up 95%), 73% of patients were hospitalized and 8% died.

2. Pathogen and Biology

West Nile Virus is a positive-sense, single-stranded RNA virus belonging to the genus Flavivirus (now also written Orthoflavivirus, with the virus named Orthoflavivirus nilense), family Flaviviridae. It is closely related to other medically important flaviviruses including dengue virus, Zika virus, yellow fever virus, Japanese encephalitis virus, and St. Louis encephalitis virus.

Genome and Structure

The WNV genome is approximately 11 kilobases encoding a single polyprotein cleaved into 3 structural proteins (capsid C, membrane protein prM/M, envelope protein E) and 7 nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5). The envelope (E) protein mediates receptor binding and membrane fusion and is the primary target of neutralizing antibodies. NS5 encodes the RNA-dependent RNA polymerase essential for viral replication and is a major drug target in flavivirus research.

Lineages

WNV exists in at least eight phylogenetic lineages. Lineage 1 (including the New York 1999 (NY99) strain introduced in 1999 and the WN02 strain that replaced it) is responsible for virtually all North American disease. Lineage 2 has caused epidemic neuroinvasive disease in southern and eastern Europe since the mid-2000s. Lineage 1 strains show higher neuroinvasiveness and virulence in corvids (crows, ravens) — dead crow surveillance became an important early warning system in North America.

Neuroinvasion Mechanisms

WNV neuroinvasion involves several mechanisms: direct infection of endothelial cells of the blood-brain barrier (BBB) leading to transcellular or paracellular viral entry; “Trojan horse” transport inside infected monocytes/macrophages; peripheral nerve axonal transport; and olfactory nerve retrograde transport. Once inside the CNS, WNV infects neurons (particularly in the brainstem, anterior horn cells of the spinal cord, cerebellum, and cortex), triggering a neuroinflammatory cascade that causes both direct viral cytopathology and immune-mediated neuronal injury.

Risk Factors for Neuroinvasive Disease

Most people who develop severe disease have identifiable risk factors:

3. Transmission and Vector Biology

Culex Mosquito Vectors

WNV is transmitted principally by mosquitoes of the genus Culex in North America:

Over 65 mosquito species have been found infected with WNV in the US, but Culex species are the primary epidemiologic drivers.

The Bird Reservoir

Birds — particularly passerine (perching) birds — are the primary amplifying hosts for WNV. Infected birds develop high-level viremia, efficiently infecting mosquitoes that feed on them. The WNV transmission cycle is an enzootic cycle (bird↔mosquito↔bird) with humans as incidental “dead-end” hosts: human blood WNV titers are too low to efficiently infect a feeding mosquito, so humans do not meaningfully amplify virus back into the mosquito population.

Corvids (American crows, ravens, blue jays) are highly susceptible to WNV and die in large numbers during outbreak years — a pattern exploited for surveillance. Many other bird species (robins, house sparrows, house finches) develop high viremia without dying and serve as efficient reservoir hosts.

Non-Vector Transmission Routes

Though rare, WNV can be transmitted via:

4. Incubation and Disease Spectrum

Incubation Period

The incubation period is typically 2–14 days from mosquito bite, with most symptomatic cases developing illness 3–8 days after exposure. Immunocompromised individuals may have longer incubation periods (up to 21 days in transplant recipients).

Disease Spectrum

5. Symptoms and Clinical Presentation

West Nile Fever (Mild Disease)

Approximately 20% of infected individuals (a 2013 review gives approximately 25%) develop a febrile illness lasting 3–6 days, with complete recovery in most patients (though fatigue may persist for weeks):

West Nile fever is clinically indistinguishable from many other viral illnesses. Without epidemiologic context (residence or travel in endemic area during mosquito season), laboratory testing is not routinely indicated for mild illness.

West Nile Neuroinvasive Disease (WNND)

Fewer than 1% of infected individuals develop neuroinvasive disease, but this small fraction accounts for the serious morbidity and mortality associated with WNV. Three neurologic syndromes are recognized:

West Nile Meningitis

Milder of the three WNND syndromes. Presents like bacterial meningitis with fever, severe headache, photophobia, phonophobia, and meningismus (nuchal rigidity), but with a viral (aseptic) cerebrospinal fluid (CSF) profile. Most patients recover fully with supportive care. Cerebrospinal fluid shows lymphocytic pleocytosis (white blood cells (WBC) typically 10–500 cells/mm³, predominantly lymphocytes), elevated protein (50–200 mg/dL), and normal or mildly low glucose.

West Nile Encephalitis

The most severe and most common form of WNND. Presents with altered level of consciousness (ranging from mild confusion to coma), seizures, focal neurologic deficits, and movement disorders. Distinctive features that may suggest WNV encephalitis over other viral encephalitides include:

West Nile Acute Flaccid Paralysis (WNV Poliomyelitis)

WNV can cause an asymmetric flaccid paralysis clinically identical to poliomyelitis, through direct anterior horn cell infection in the spinal cord. This syndrome presents as acute asymmetric limb weakness, often with rapid progression to complete flaccid paralysis of one or more limbs, absent deep tendon reflexes, and preserved sensation. Bulbar involvement and respiratory muscle paralysis can occur. Electromyography (EMG) and nerve conduction studies show an axonal motor neuropathy pattern consistent with anterior horn cell disease. Prognosis for limb recovery is poor; permanent weakness is common: a 2013 review reports that approximately two-thirds of those with paralysis remain with significant weakness in affected limbs. Some patients require long-term mechanical ventilation.

6. Diagnosis

Serology: IgM ELISA (Preferred Initial Test)

Detection of WNV-specific immunoglobulin M (IgM) antibodies in cerebrospinal fluid (CSF) or serum by enzyme-linked immunosorbent assay (ELISA) is the most commonly used diagnostic approach and is considered the standard of care for suspected WNND:

Polymerase Chain Reaction

WNV RNA can be detected by reverse-transcription polymerase chain reaction (RT-PCR) in serum during the brief viremic phase (approximately 1–7 days after infection onset). By the time most patients present with neuroinvasive disease, viremia has cleared and reverse-transcription polymerase chain reaction on serum is typically negative. Cerebrospinal fluid polymerase chain reaction (PCR) for WNV is also insensitive (<60%). Serology is therefore preferred over polymerase chain reaction for WNV diagnosis in the clinical setting. Polymerase chain reaction is most useful in immunocompromised patients (who may not mount an adequate antibody response) and for blood donor screening.

Cerebrospinal Fluid Analysis

Lumbar puncture is indicated for all patients with suspected WNV meningitis or encephalitis:

Magnetic Resonance Imaging Brain

Magnetic resonance imaging findings in WNV encephalitis are variable and may be normal in many patients. When abnormal, signal changes (hyperintensities on T2/FLAIR) are most commonly seen in the basal ganglia, thalami, brainstem (especially substantia nigra), cerebellum, and spinal cord anterior horn regions — a pattern that can be suggestive. Enhancement after contrast may be seen in meningeal or parenchymal lesions.

7. Treatment

There is no specific antiviral treatment for West Nile Virus infection in humans. No antiviral drug has been approved or proven effective in clinical trials for WNV. Treatment is entirely supportive.

Investigational Antivirals

Several agents have been studied but not proven effective in clinical trials:

Supportive Care for WNND

8. Home Care and Supportive Management

For the approximately 20% of WNV-infected people who develop West Nile fever (mild disease), recovery at home with supportive care is usual:

Signs during a mild illness that hospitals treat as urgent:

People at high risk (age 60+, immunocompromised, diabetes) who develop fever during mosquito season in an endemic area have a higher risk of progression to neuroinvasive disease, even with initially mild symptoms.

9. Complications

Neurologic Sequelae in WNND Survivors

Long-term outcomes after WNND are often poor, but they vary by form. A 2013 review reports that encephalitis often leaves considerable long-term illness and that about two-thirds of people with paralysis keep significant weakness. An 8-month follow-up of 16 patients found favorable outcomes after meningitis or encephalitis, although fatigue, headache and muscle pain persisted, gait and movement disorders persisted in 6, and patients with flaccid paralysis did not recover limb strength. Follow-up studies of WNND survivors show that many patients do not fully recover:

Mortality

Among those with neuroinvasive disease, the overall case fatality rate is approximately 9%. Fatality is much higher in the elderly: approximately 17% in adults 70+. Encephalitis is more lethal than meningitis or flaccid paralysis in terms of acute mortality.

Long-Term Kidney Disease

Emerging evidence suggests a link between WNV infection and chronic kidney disease (CKD) and proteinuria (protein in the urine) in the years following infection. A Houston cohort study by Nolan and colleagues tested 139 people with a past WNV diagnosis, most of them four to nine years after infection: 40% had evidence of chronic kidney disease (30% stage I–II, 10% stage III or greater) and 26% had proteinuria. Only a history of neuroinvasive disease was independently associated with chronic kidney disease, and traditional risk factors were not. The abstract names no uninfected comparison group, so the study reports how common kidney disease was in survivors, not a measured increase over people never infected. Animals in experimental infections develop chronic kidney infection with tissue changes for up to 8 months. The mechanism may involve persistent low-level renal inflammation or direct viral nephropathy.

Post-WNV Fatigue Syndrome

A substantial proportion of WNV fever patients (not just neuroinvasive cases) report persistent fatigue, cognitive difficulties, and myalgias months after the acute illness — a post-viral syndrome analogous to post-COVID or post-polio syndrome. This is an active area of research and is under-recognized in clinical practice.

10. Prevention

There is no licensed human vaccine for West Nile Virus (several veterinary vaccines are licensed for horses). Prevention relies on mosquito control at the community and personal level.

A 2024 meeting convened by the U.S. Centers for Disease Control and Prevention named the barriers to a human vaccine: irregular outbreaks that vary by place and year and make efficacy trials hard to run, a high share of symptom-free infections, no agreed lab marker that predicts protection, a need for standard antibody tests, and minimal economic support. In an open-label phase 1 trial, a subunit vaccine candidate (HBV-002) was generally safe and raised virus-neutralizing antibodies in all who received it, but the antibody levels declined over time.

Personal Protection from Mosquitoes

How Mosquito Breeding Sites Are Removed

Community Mosquito Control

Municipal and county health departments conduct WNV surveillance (dead bird surveillance, mosquito trap monitoring, human case surveillance) and spray adulticide (e.g., pyrethrin-based insecticides) when threshold WNV activity is detected. Aerial and ground-based spraying is used to reduce adult mosquito populations and WNV transmission during outbreaks. A 2013 review describes a shift to aggressive adult mosquito control during outbreaks and calls pesticide exposure and adverse human health events after these operations negligible. The summary of a 2024 meeting convened by the U.S. Centers for Disease Control and Prevention states that attempts to lessen the impact of WNV by vector control “have been largely unsuccessful”.

Blood Supply Safety

Since 2003, all donated blood in the US is screened for WNV RNA by NAT. Minipool NAT testing (testing pools of 6–16 donations) is standard; individual NAT testing is activated in high-transmission regions during outbreak periods. This system has prevented thousands of transfusion-associated WNV infections annually.

Key Research Papers

  1. Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001;344(24):1807–1814. — PubMed PMID: 11407341 · doi:10.1056/NEJM200106143442401
  2. Petersen LR, Brault AC, Nasci RS. West Nile virus: review of the literature. JAMA. 2013;310(3):308–315. — PubMed PMID: 23860989 · doi:10.1001/jama.2013.8042
  3. Davis LE, DeBiasi R, Goade DE, et al. West Nile virus neuroinvasive disease. Ann Neurol. 2006;60(3):286–300. — PubMed PMID: 16983682 · doi:10.1002/ana.20959
  4. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis. 2005;11(8):1174–1179. — PubMed PMID: 16102303 · doi:10.3201/eid1108.050289b
  5. Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med. 2002;137(3):173–179. — PubMed PMID: 12160365 · doi:10.7326/0003-4819-137-3-200208060-00009
  6. Sejvar JJ, Haddad MB, Tierney BC, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA. 2003;290(4):511–515. — PubMed PMID: 12876094 · doi:10.1001/jama.290.4.511
  7. Kleinschmidt-DeMasters BK, Marder BA, Levi ME, et al. Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. Arch Neurol. 2004;61(8):1210–1220. — Search PubMed · doi:10.1001/archneur.61.8.1210
  8. Murray KO, Mertens E, Despres P. West Nile virus and its emergence in the United States of America. Vet Res. 2010;41(6):67. — Search PubMed · doi:10.1051/vetres/2010039
  9. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med. 2006;203(1):35–40. — PubMed PMID: 16418398 · doi:10.1084/jem.20051970
  10. Nolan MS, Podoll AS, Hause AM, Akers KM, Finkel KW, Murray KO. Prevalence of chronic kidney disease and progression of disease over time among patients enrolled in the Houston West Nile virus cohort. PLoS One. 2012;7(7):e40374. — PubMed PMID: 22792293 · doi:10.1371/journal.pone.0040374
  11. Murray KO, Walker C, Gould E. The virology, epidemiology, and clinical impact of West Nile virus: a decade of advancements in research since its introduction into the Western Hemisphere. Epidemiol Infect. 2011;139(6):807–817. — Search PubMed · doi:10.1017/s0950268811000185
  12. Petersen LR, Roehrig JT. West Nile virus: a reemerging global pathogen. Emerg Infect Dis. 2001;7(4):611–614. — PubMed PMID: 11585520 · doi:10.3201/eid0704.017401
  13. Padda H, Jacobs D, Gould CV, et al. West Nile Virus and Other Nationally Notifiable Arboviral Diseases - United States, 2023. MMWR Morb Mortal Wkly Rep. 2025;74(21):358–364. — PubMed PMID: 40504766 · doi:10.15585/mmwr.mm7421a1
  14. Mace KE, Jacobs D, Gould CV, et al. West Nile Virus and Other Nationally Notifiable Arboviral Diseases - United States, 2024. MMWR Morb Mortal Wkly Rep. 2026;75(29):369–376. — PubMed PMID: 42531165 · doi:10.15585/mmwr.mm7529a1
  15. Nett RJ, Brault AC, Lambert AJ, et al. Summary of human West Nile virus vaccine meeting, 2024: Investigating barriers to development. Vaccine. 2025;68:127938. — PubMed PMID: 41197444 · doi:10.1016/j.vaccine.2025.127938
  16. Coller BG, Clements DE, Yelmene M, et al. A Phase 1, Open Label, Safety Study of HBV-002 (West Nile Recombinant Subunit Vaccine) in Healthy Adults. Am J Trop Med Hyg. 2026;115(2):366–371. — PubMed PMID: 42167201 · doi:10.4269/ajtmh.26-0124
  17. Zulli A, Duong D, Shelden B, et al. West Nile Virus (Orthoflavivirus nilense) RNA concentrations in wastewater solids at five wastewater treatment plants in the United States. PeerJ. 2025;13:e19748. — PubMed PMID: 40718785 · doi:10.7717/peerj.19748

PubMed Topic Searches

Live PubMed queries for current peer-reviewed literature on West Nile Virus:

  1. PubMed: West Nile virus review
  2. PubMed: West Nile neuroinvasive disease
  3. PubMed: West Nile virus encephalitis
  4. PubMed: West Nile acute flaccid paralysis
  5. PubMed: West Nile virus US epidemiology
  6. PubMed: West Nile IgM serology diagnosis
  7. PubMed: Culex mosquito West Nile transmission
  8. PubMed: DEET mosquito repellent efficacy
  9. PubMed: West Nile virus long-term outcomes
  10. PubMed: West Nile virus blood transfusion safety

Back to Table of Contents

Connections

Back to Table of Contents